Synthekine Inc., an engineered cytokine therapeutics company, today announced that updated clinical and translational data from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK ...

Two abstracts accepted for presentationOne abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01Another abstract on the use of Evaxion’s AI-Immunology™ ...

TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...

Dr. Maluf emphasized that his discussion would focus on penile squamous cell carcinoma and genitourinary basket trials. At ...

Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY(R) ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for ...

LITESPARK-011 demonstrated improved progression-free survival with the combination of belzutifan plus lenvatinib vs ...

Dr. Alexandre Zlotta delivered the State-of-the-art lecture Who really needs surgery after neo-adjuvant chemotherapy? Dr.

The company will now assess the available data to determine its next steps in progressing efti’s development across multiple ...

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS ...

A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.

Aditxt Inc. (NASDAQ:ADTX) announced it has acquired Ignite Proteomics LLC, a precision oncology company specializing in ...